TB-500 (Thymosin Beta-4 Fragment): A Laboratory Research Reference

TB-500 is a synthetic peptide corresponding to a fragment of thymosin beta-4, a naturally occurring actin-sequestering protein. In the research literature it is studied for its interactions with cell migration, actin dynamics, and tissue-repair signalling pathways. The name "TB-500" refers to this specific thymosin beta-4 fragment, distinct from the full-length protein.

This page is a non-promotional scientific reference for researchers. It summarises the chemical identity, sequence basis, molecular characteristics, research background, and analytical testing of TB-500. It does not provide recovery, injury, therapeutic, or human-use guidance of any kind. TB-500 supplied by Bulk Aussie Peptides is for laboratory research purposes only.

Chemical Identity and Sequence Basis

TB-500 is derived from the N-terminal region of thymosin beta-4, a protein found widely across mammalian cells. The key sequence in this region is the actin-binding motif that gives thymosin beta-4 its characteristic interaction with monomeric actin. TB-500 is studied as a tool to interrogate the actin-related functions of the full protein in a defined, synthetic form.

As a synthetic peptide, TB-500 is assembled stepwise in the laboratory, then purified and characterised before it is supplied for research. For background on how research peptides are produced, see the synthetic peptides research guide.

Molecular Characteristics

• Classification: a synthetic fragment peptide derived from the actin-binding region of thymosin beta-4.
• Sequence basis: corresponds to a short, defined segment of the parent protein; the exact sequence used in a study should be read from that study’s methods section.
• Molecular weight: calculated from the amino acid sequence and reported in Daltons (Da).
• Physical form: supplied as a lyophilised (freeze-dried) powder.

Laboratory Research Background

The research literature describes investigations into TB-500 within cellular and animal models, focusing on actin dynamics, cell migration, and processes related to tissue repair. These studies are exploratory and conducted in vitro or in approved animal research models. They do not establish a therapeutic use in humans.

It is important to distinguish research findings from medical claims. TB-500 has not been established as a safe or effective medicine, and no regulatory approval for human therapeutic use is implied by its study in the laboratory. For a comparison with a related repair-pathway peptide, see the BPC-157 versus TB-500 comparison.

Analytical Testing

As with other research peptides, TB-500 is characterised using:

• HPLC for purity assessment.
• Mass spectrometry for identity confirmation by molecular mass.

Guidance on reading these documents is available in the article on how to read a peptide Certificate of Analysis.

References and Further Reading

• Thymosin beta-4 and the TB-500 fragment. (Preclinical research literature on actin binding and cell-migration signalling.)
• BPC-157 vs TB-500 — a detailed comparison.
• Reading a Peptide Certificate of Analysis.